Celldex Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Celldex Therapeutics (CLDX).

Price Target Range — 13 Quarters

Analyst Consensus — 14 Analysts

13Buy

1Hold

Consensus RatingBuy# Analysts14Avg. Consensus PT$61Upside to Avg. PT+108.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$64
Sep 23, 2026	Leerink Partners	Thomas Smith	PT Raise	Outperform	$70→$88
Sep 23, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$50→$57
Sep 22, 2026	HC Wainwright & Co.	Joseph Pantginis	PT Raise	Buy	$42→$64
Sep 22, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$61→$72
Sep 10, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$46→$50
Aug 7, 2026	Morgan Stanley	Judah Frommer	PT Raise	Overweight	$40→$46
Aug 7, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$48→$53
Jul 29, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$48→$72
Jul 22, 2026	Wells Fargo	Derek Archila	PT Cut	Overweight	$54→$48
Jul 22, 2026	Morgan Stanley	Judah Frommer	PT Cut	Overweight	$44→$40
Jul 22, 2026	Cantor Fitzgerald	Kristen Kluska	PT Cut	Overweight	$67→$61
Jul 22, 2026	Canaccord Genuity	Edward Nash	PT Cut	Buy	$62→$60
Jul 20, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$90→$100
Jun 15, 2026	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$42
Jun 10, 2026	UBS	David Dai	PT Raise	Buy	$38→$45
May 13, 2026	Wells Fargo	Derek Archila	PT Raise	Overweight	$38→$54
May 8, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$45→$48
Apr 20, 2026	Barclays	Etzer Darout	Upgrade	Underweight→Overweight	$24→$45
Mar 2, 2026	Goldman Sachs	Richard Law	PT Raise	Neutral	$30→$34

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $64 price target.

Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88

Leerink Partners analyst Thomas Smith maintains Celldex Therapeutics (NASDAQ:CLDX) with a Outperform and raises the price target from $70 to $88.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $50 to $57.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $42 to $64.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

Cantor Fitzgerald analyst Kristen Kluska maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $61 to $72.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

Morgan Stanley analyst Judah Frommer maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and raises the price target from $46 to $50.

Benzinga Newsdesk

Celldex Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Celldex Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target

PRO
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

PRO
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

PRO
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

People Also Watch

People Also Watch

Celldex Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Celldex Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target

PROLeerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88

PROMorgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

PROHC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

PROCantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

PROMorgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target

PRO
Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

PRO
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

PRO
Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

PRO
Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50